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Abstract
Plasmodium falciparum infection results in adhesion of infected erythrocytes to blood vessel endothelium, and acute
endothelial cell activation, together with sequestration of platelets and leucocytes. We have previously shown that patients
with severe infection or fulminant cerebral malaria have significantly increased circulatory levels of the adhesive
glycoprotein von Willebrand factor (VWF) and its propeptide, both of which are indices of endothelial cell activation. In this
prospective study of patients from Ghana with severe (n = 20) and cerebral (n = 13) P. falciparum malaria, we demonstrate
that increased plasma VWF antigen (VWF:Ag) level is associated with disproportionately increased VWF function. VWF
collagen binding (VWF:CB) was significantly increased in patients with cerebral malaria and severe malaria (medians 7.6 and
7.0 IU/ml versus 1.9 IU/ml; p,0.005). This increased VWF:CB correlated with the presence of abnormal ultra-large VWF
multimers in patient rather than control plasmas. Concomitant with the increase in VWF:Ag and VWF:CB was a significant
persistent reduction in the activity of the VWF-specific cleaving protease ADAMTS13 (,55% of normal; p,0.005). Mixing
studies were performed using P. falciparum patient plasma and normal pooled plasma, in the presence or absence of
exogenous recombinant ADAMTS13. These studies demonstrated that in malarial plasma, ADAMTS13 function was
persistently inhibited in a time-dependent manner. Furthermore, this inhibitory effect was not associated with the presence
of known inhibitors of ADAMTS13 enzymatic function (interleukin-6, free haemoglobin, factor VIII or thrombospondin-1).
These novel findings suggest that severe P. falciparum infection is associated with acute endothelial cell activation,
abnormal circulating ULVWF multimers, and a significant reduction in plasma ADAMTS13 function which is mediated at
least in part by an unidentified inhibitor.
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Introduction
In spite of the significant mortality associated with P. falciparum
infection, the molecular mechanisms involved in its pathophysi-
ology remain poorly understood. However, sequestration of P.
falciparum-infected erythrocytes (IE) in the microvasculature of vital
organs including the brain and placenta plays a key role in this
process [1]. Previous studies have demonstrated that sequestration
involves adhesion of IE to endothelial cell (EC) surfaces. This
process is mediated by various parasite-related ligands, including
P. falciparum erythrocyte membrane protein 1 (PfEMP1), expressed
on the surface of IE [2]. Furthermore, a number of specific
receptors expressed on EC surfaces are important in regulating IE
adhesion, including thrombomodulin, CD36, thrombospondin,
intercellular adhesion molecule-1 (ICAM-1), vascular adhesion
molecule-1 (VCAM-1), P-selectin and E-selectin. Expression of
these receptors varies significantly between different vascular beds,
and can be regulated in response to inflammatory cytokines (e.g.
TNF and interleukin-1) [3,4]. Consequently, EC activation plays a
critical role in regulating IE cytoadherence [5].
Von Willebrand factor (VWF) is a large plasma glycoprotein
that plays a critical role in primary haemostasis by mediating the
adhesion of platelets to sites of vascular injury [6]. In vivo VWF
biosynthesis is limited to EC and megakaryocytes [7]. VWF
synthesised within EC is either constitutively secreted into the
plasma, or alternatively stored within specific intracellular
organelles known as Weibel-Palade (WP) bodies [8]. Following
EC activation by a variety of secretagogues including thrombin,
fibrin and histamine, VWF and its propeptide are secreted in
equimolar concentrations from the WP bodies [9]. We recently
reported marked increased plasma VWF and VWF propeptide
levels in severe P. falciparum infection, consistent with acute EC
activation [10]. Indeed, children with cerebral malaria (CM) had
VWF propeptide levels exceeding those typically observed in
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fulminant vascular diseases such as thrombotic thrombocytopenic
purpura (TTP) [11]. Subsequently, a study of 14 healthy
volunteers infected with P. falciparum showed that the increased
plasma VWF and VWF propeptide levels develop soon after the
onset of blood stage infection [12]. Consequently, acute EC
activation constitutes an early feature of P. falciparum malaria
infection, and may therefore be important in the pathogenesis of
progression to severe or cerebral malaria respectively.
Plasma VWF plays a critical role in primary haemostasis by
mediating the adhesion of platelets to sites of vascular injury [6,8].
Following endothelial disruption, VWF binds to exposed collagen
in the subendothelial matrix. This anchored VWF undergoes
marked conformational changes in response to shear stress exerted
by the circulating blood, and can then tether platelets through
specific binding of the platelet Gp Ib-IX-V receptor [9,13].
Accumulating evidence suggests that platelet adhesion and
aggregation may play important roles in facilitating cytoadhesion
of P. falciparum IE to activated EC [14–16]. However, it remains
unclear if the increased plasma VWF levels play any direct role in
mediating this process, or whether they merely serve as a marker
of acute EC activation. Nevertheless, elegant studies using a novel
llama-derived nanobody have demonstrated that a significant
proportion of circulating plasma VWF in P. falciparum infected
patients is present in an active platelet GpIb-binding conformation
[12]. Furthermore, plasma VWF:Ag levels in patients with malaria
inversely correlate with platelet count [12], and we have previously
shown that plasma VWF propeptide levels correlate with other
established biochemical markers of malaria severity, including
plasma lactate [10].
To further elucidate the mechanism responsible for quantitative
and qualitative variations in plasma VWF levels in malaria, we
collected plasma samples from a cohort of children with laboratory
confirmed severe P. falciparum infection, or full-blown cerebral
malaria. We demonstrate herein that severe P. falciparum malaria is
associated not only with increased plasma VWF antigen (VWF:Ag)
levels, but an even more marked increase in VWF activity as
determined by collagen binding assay (VWF:CB), due to the
presence of abnormal circulating ultra-large VWF (ULVWF)
multimers. In addition, we also demonstrate that the presence of
ULVWF is associated with a significant reduction in plasma levels
of the VWF cleaving protease ADAMTS13 (A Disintegrin And
Metalloproteinase with ThromboSpondin type-1 repeats), and an
unidentified inhibitor of ADAMTS13 activity present in the
plasma of children with severe P. falciparum.
Methods
Patients
Patients were recruited from those presenting with severe malaria
to the Komfo Anokye Teaching Hospital in Kumasi, Ghana, as
previously described [10]. Subjects were children aged between 6
months and 6 years, recruited after written informed consent had
been obtained. Ethical approval was granted by the committee on
human research, publications and ethics (CHRPE), School of
Medical Sciences, University of Science and Technology, Kumasi,
and also by the Liverpool School of Tropical Medicine research
ethics committee. For each subject, clinical details were obtained at
presentation, and P. falciparum infection confirmed on thick blood
films. Venous blood samples were collected, before standard anti-
malarial treatment was commenced in all patients.
Cerebral malaria was defined as a Blantyre coma score of two or
less in a child with malarial parasitaemia, and without any other
cause of coma (e.g. hypoglycaemia or meningitis) [17]. For the
cohort of children with cerebral malaria (n=13), follow-up samples
were also collected at 24 and 72 hours respectively, following
admission and after commencement of treatment. Non-cerebral
severe malaria was defined according to standard World Health
Organization criteria (WHO, 2000), which included severe anaemia
(,5 g/dl), prostration, convulsions, and respiratory distress (n= 20),
but which did not meet the criteria for cerebral malaria. Finally,
healthy controls (n= 25) were recruited from children attending for
immunisation, surgery, or outpatient surgical review.
VWF and ADAMTS13 antigen and activity assays
From each patient and control, 1.2 ml of venous blood was
collected into 3.2% citrate (1:9 vol/vol), and immediately placed
on ice. After centrifugation at 3000 g for 20 min at 4uC, plasma
aliquots were stored at 280uC. Plasma VWF:Ag levels were
performed as previously described [10,18]. VWF:CB levels were
determined using a commercial ELISA method (Technoclone,
UK) as before [19]. VWF multimer analysis was performed
according to Ruggeri et al with minor modifications [20]. Sodium
dodecyl sulfate (SDS)-agarose gel electrophoresis was performed
using 1.5% agarose gels, and VWF multimer composition,
visualised using HRP-labelled polyclonal rabbit anti-human
VWF (Dako, Glostrup, Denmark). For objectively quantifying
differences in VWF multimer composition, densitometry was
performed using ImageJ software (Image Processing and Analysis
in Java). ADAMTS13 activity was determined by FRETS-VWF73
assay (Peptides International, Kentucky, USA), and ADAMTS13
antigen levels by ELISA using murine monoclonal antibodies (kind
gift of Dr H. Feys, Washington University, Saint Louis, USA) as
previously reported [21].
ADAMTS13 inhibitor studies
To investigate ADAMTS13 inhibition, individual malaria plasmas
(n=4) were mixed in different proportions (25%:75% or 50%:50%)
with pooled normal plasma. ADAMTS13 activity using the FRETS-
VWF73 assay (Peptides International, Kentucky, USA), was assessed
immediately following mixing, and after incubation at 37uC for
15 min or 30 min respectively. Recombinant human ADAMTS13
(cDNA kind gift of Dr R. Montgomery, Medical College of
Author Summary
Malaria is caused by infection of red blood cells
(erythrocytes) with protozoan parasites of the genus
Plasmodium. Infected erythrocytes adhere to and disrupt
the inner lining, or endothelium, of small blood vessels,
especially those of the brain, resulting in blockage and
subsequent cerebral malaria. We have studied the effect of
Plasmodium falciparum infection on the endothelial cell
activation marker, the multimeric adhesive protein von
Willebrand factor (VWF) in a cohort of patients with severe
infection or cerebral malaria. We demonstrate that malarial
infection in these patients is associated with abnormally
high levels of ultra-large VWF in blood plasma, and that
VWF functional ability as measured by collagen binding is
disproportionately increased as compared to normal
plasmas. Circulating levels of the VWF-specific cleaving
enzyme ADAMTS13 is reduced to ,55% of normal in
patients, and plasma mixing studies demonstrate the
presence of an inhibitor of ADAMTS13 function. Thus,
severe P. falciparum infection results in disruption of the
endothelium, causing release of ultra-large VWF. Together
with reduced ADAMTS13 levels, and an unidentified
inhibitor of ADAMTS13, this may contribute to the
pathophysiology of malaria.
Malaria, VWF and ADAMTS13 Inhibition
PLoS Pathogens | www.plospathogens.org 2 March 2009 | Volume 5 | Issue 3 | e1000349
Wisconsin, USA) was stably expressed in HEK293 cells, and purified
as previously described [18]. Recombinant ADAMTS13 was
adjusted to normal pooled plasma activity level (1 U/ml) and then
added to P. falciparum-infected (n=4), or control plasma samples
(n=4), and ADAMTS13 activity timecourse assessed as above
(FRETS-VWF73 assay). Finally, plasma concentrations of IL-6
(Abcam, Cambridge, UK) and TSP-1 (R&D systems, Minneapolis,
USA) were measured using commercial ELISA kits, in accordance
with the manufacturer’s instructions, and plasma haemoglobin levels
were measured using a Sysmex XE 5000 analyser. No red cells were
detected in the platelet poor plasma preparations.
Statistical analysis
All statistical analyses were performed using the SPSS statistics
package (version 4.02, SPSS Inc), and statistical significance was
assigned at a value of p,0.05. Normally distributed data are
presented as mean +/2 SEM, and differences between patients
and controls analyzed using the two sample Student’s t test. For
nonparametric data, medians and ranges were calculated and
nonparametric tests for statistical significance were performed
using Mann-Whitney test.
Results
Severe P. falciparum malaria influences plasma VWF
multimer composition
In children with cerebral (CM) and non-cerebral severe (SM) P.
falciparum malaria, plasma VWF:Ag levels were significantly elevated
at presentation (medians 3.1 and 3.4 IU/ml; p,0.05) (Fig 1A). In
addition, plasma VWF activity levels (VWF:CB) were also markedly
increased (medians 7.6 and 7.0 IU/ml; p,0.05). In the CM cohort,
plasma VWF:Ag levels remained elevated during the 72 hours
following admission (Fig 1B). In contrast, VWF:CB activity
decreased progressively over this same time period (Time 0 hrs –
7.6 IU/ml; 24 hrs – 6.1 IU/ml; 72 hrs – 5.0 IU/ml respectively,
p= 0.03), in a manner similar to that previously reported for VWF
propeptide levels [10]. Although plasma VWF:Ag and VWF:CB
were both increased in children with CM or SM at initial
presentation, the observed increase in VWF:CB was much greater
compared to that in plasma VWF:Ag levels, so that the ratio of
CB:Ag was consistently increased compared to that observed in
healthy control children (Fig 1C). Moreover, in the cohort of
children with CM, despite the progressive reduction in plasma
VWF:CB activity following admission to hospital and commence-
ment of anti-malarial therapy (Fig 1B), the ratio of VWF:Ag to
VWF:CB still remained skewed even 72 hours after initiation of anti-
malarial therapy (data not shown).
It is well-established that the VWF:CB is particularly sensitive to
circulating high molecular weight multimer (HMWM) VWF [22].
VWF multimer analysis and densitometry confirmed that
abnormal ultra-large (UL) VWF multimers were present in the
plasma of children with either CM or SM respectively (Fig 2).
Furthermore, these abnormal multimers were not observed in the
plasma of normal Ghanaian children. Cumulatively, these data
further support the hypothesis that acute endothelial cell activation
constitutes a hallmark of severe P. falciparum infection, but also
confirm the presence of abnormal circulating ULVWF multimers
in malarial plasma.
Plasma ADAMTS13 antigen and activity in severe P.
falciparum malaria
ADAMTS13 regulates normal plasma VWF multimer compo-
sition and thereby activity, through cleavage at the Tyr 1605- Met
1606 bond within the VWF A2 domain [9,23]. To determine the
Figure 1. Severe Plasmodium falciparum malaria influences
plasma VWF antigen level and collagen binding activity. (A)
Plasma VWF:Ag levels (white bars – left Y axis) were measured by ELISA,
and VWF activity by collagen binding activity (VWF:CB) (grey bars – right
Y axis). Each plasma sample was tested in duplicate at three dilutions,
and median values for each group are shown. VWF:Ag and VWF:CB
levels were markedly elevated in patients with cerebral malaria and in
children with severe malaria at presentation compared to levels in
healthy control children. (B) In a cohort of children with cerebral
malaria (CM), the time-course of VWF:Ag and VWF:CB levels following
admission and commencement of anti-malarial therapy was assessed
using follow-up plasma samples collected after 24 and 72 hours
respectively. (C) Although both VWF:Ag and VWF:CB were increased in
all cases of P. falciparum malaria, the relative increase observed in
plasma VWF:CB levels was significantly higher (p,0.05), such that the
ratio of CB to Ag was consistently .1 in children with CM (n= 13; N) or
SM (n= 20; m) at presentation compared to healthy control subjects
(n = 25; %). (Hashed line indicates 1:1 ratio).
doi:10.1371/journal.ppat.1000349.g001
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molecular mechanism(s) responsible for the markedly increased
VWF:CB and circulating ULVWF in severe malaria infection, we
investigated plasma ADAMTS13 levels in children with CM, SM
and normal healthy controls.
Although plasma ADAMTS13 antigen and activity levels were
previously shown to be markedly reduced in neonates [21], normal
ADAMTS13 levels have not previously been described for older
African children. In our normal control children (minimum age 6
months), median ADAMTS13 activity levels were 1.07 U/ml
(children aged 6–12 months; n = 10) and 1.23 U/ml (children 1–
6 years; n = 15). These levels were not significantly different
(p = 0.45), and fell well within our normal adult plasma
ADAMTS13 activity range. In addition, plasma ADAMTS13
activity levels were not significantly influenced by gender. These
findings are consistent with another recent study that determined
plasma ADAMTS13 levels in a cohort of U.K. children [24].
ADAMTS13 antigen levels were significantly lower in children
with severe malaria at presentation than in controls (Fig 3A).
Similarly, plasma ADAMTS13 activity levels were also significantly
reduced in both CM (median=0.63 U/ml; p,0.001; Mann
Whitney) and SM (median=0.56 U/ml; p,0.001) at initial
presentation (Fig 2B). Furthermore, in the cohort of children with
CM, ADAMTS13 activity remained significantly reduced during the
subsequent 72 hour follow-up period. Although ADAMTS13
antigen and ADAMTS13 activity levels were reduced to comparable
degrees in most children with SM and CM, four patients were
identified with reduced activity:antigen ratios (,0.7). These novel
data are consistent with a recent report of acquired ADAMTS13
deficiency in paediatric patients with other causes of severe sepsis
[25], but contrast with the previous findings of de Mast et al, who
reported normal plasma ADAMTS13 activity by FRETS-VWF73
assay during the early stages of P. falciparum infection [12].
Inhibition of ADAMTS13 activity in severe P. falciparum
plasma
To investigate whether the reduction in ADAMTS13 activity in
malaria plasma might be attributable to the presence of an inhibitor,
we performed mixing studies of malaria and normal plasma
respectively. Following immediate mixing, no ADAMTS13 inhibi-
tion was apparent (Fig 4A). However following incubation at 37uC,
clear evidence of a time-dependent inhibitory effect was observed
(Fig 3B). Indeed, ADAMTS13 activity in normal plasma was
reduced by approximately 60% after pooled normal plasma was
incubated in a 75%:25% mix with malarial plasma for 30 mins.
Similar levels of inhibition were observed using four different malaria
plasma samples, but not after similar incubation with normal control
plasmas. This ability of malaria plasma to directly inhibit
ADAMTS13 activity was confirmed by spiking malarial plasmas
with recombinant human ADAMTS13 (Fig 3C). Once again,
significant time-dependent inhibition of FRETS-VWF73 activity
Figure 2. Cerebral, and non-cerebral severe Plasmodium
falciparum malaria, are associated with abnormal high molec-
ular weight VWF multimers. (A) Plasma VWF multimer distribution
was analysed by non-reducing agarose gel electrophoresis. Plasma from
children with severe P. falciparum (MP1, MP2, MP3, MP4, MP5)
demonstrated abnormal HMW-VWF multimers which were not ob-
served in normal pooled plasma (NPP), nor in healthy control children
(NP1, NP2, NP3). Plasma from a patient with known type 2A von
Willebrand disease (with characteristic loss of multimers) has been
included as negative control (VWD). (B) Densitometric scans of the
lanes in (A). Individual panels correspond with individual lanes. The
horizontal axis is optical density. Abnormal HMW multimers are present
in MP1 to MP5 (highlighted by bands extending beyond arbitrary line)
but not apparent in NPP or healthy controls (NP1 to NP3).
doi:10.1371/journal.ppat.1000349.g002
Figure 3. Effect of severe P. falciparum malaria infection on
plasma ADAMTS13 antigen and activity. (A) Plasma ADAMTS13
antigen levels were significantly reduced in children with CM
(median = 0.6 U/ml; p,0.005; Mann Whitney) and SM (med-
ian = 0.55 U/ml; p,0.005) at presentation compared to healthy control
children. Furthermore, in the CM cohort, ADAMTS13 antigen levels
remained significantly reduced at 24 hrs and 72 hrs following
commencement of anti-malarial therapy. (* p,0.05; ** p,0.005; ***
p,0.0005). (B) Plasma ADAMTS13 activity levels, determined by FRETS-
VWF73 assay, were also significantly reduced in cases of both CM
(median = 0.63 U/ml; p,0.005: Mann Whitney) and SM (med-
ian = 0.56 U/ml; p,0.005) compared to healthy controls.
doi:10.1371/journal.ppat.1000349.g003
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was observed in the plasmas of children with severe P. falciparum
(p,0.001), but not in normal control plasmas.
Effects of severe P. falciparum malaria on ADAMTS13
inhibitors in plasma
Proteins suggested to regulate the ability of plasma ADAMTS13
to cleave full-length VWF include interleukin 6 (IL-6) [26],
thrombospondin-1 (TSP-1) [27], thrombin and plasmin [19], free
plasma haemoglobin [28], and most recently reduced factor VIII
(FVIII) levels [29]. We found that plasma IL-6 levels were
significantly elevated at presentation in children with either CM
(mean 240 pg/ml; p,0.001; Student’s t-test) or SM (mean
217 pg/ml; p = 0.01) compared to normal controls (Fig 4A).
However, although plasma IL-6 levels were increased in these
children, the levels did not approach those previously reported
necessary to inhibit ADAMTS13 activity [26]. Furthermore, in
spiking experiments we found no inhibitory effect of IL-6 (final
concentration range 0.01–10 mg/ml) in a static ADAMTS13
activity assay (Fig 4B). Disseminated intravascular coagulopathy
(DIC) is associated with enhanced thrombin generation, and
consumption of circulating FVIII, both of which can inhibit VWF
proteolysis by ADAMTS13 [19,29]. However, in children with
CM or SM respectively, we observed significantly increased
plasma FVIII:C levels (Fig 4C), confirming previous reports
suggesting that fulminant DIC is a rare complication of severe
malaria [30,31]. Intravascular haemolysis is a recognised compli-
cation of malarial infection. Moreover, increased plasma haemo-
globin has previously been described to inhibit ADAMTS13
activity [28,32]. In children with CM or SM, we observed only
minor increased plasma haemoglobin concentrations (Fig 4D),
well below that previously described to significantly inhibit
ADAMTS13 activity [28]. Finally, in contrast to the increased
plasma levels of IL-6 and FVIII:C, we found that plasma TSP-1
levels were not significantly elevated in children with either CM or
SM compared to pooled normal plasma (data not shown).
Discussion
VWF undergoes complex post-translational modification within
EC prior to secretion, including two distinct polymerization steps [7].
Dimerisation occurs within the ER, through the formation of inter-
subunit C-terminal disulphide bonds. Subsequently in the Golgi,
VWF dimers are formed into multimers through another round of
N-terminal disulphide bond formation. Consequently, VWF is
constitutively secreted into the plasma as multimers of varying size
[7,9]. In contrast, VWF stored within WP bodies exists predomi-
nantly as ULVWF multimers that are released into plasma in
response to EC activation [33,34]. The multimeric composition of
VWF is a critical determinant of its functional activity. Larger VWF
multimers bind collagen and activated platelets with ,100 fold
higher affinities compared to monomers, and are thus more efficient
in inducing platelet aggregation [9,13]. In this study, we demonstrate
that severe P. falciparummalaria is associated with an accumulation of
hyper reactive ULVWF multimers in the plasma, and thereby a
marked increase in plasma VWF activity (Fig 1). The mechanism(s)
responsible for this accumulation of abnormal ULVWF remains
unclear. However we recently demonstrated that severe P. falciparum
malaria results in fulminant, acute EC activation together with
marked exocytosis of WP bodies, which are responsible for the
majority of the increase in plasma VWF levels [10].
Following secretion, ULVWFmultimers released fromWP bodies
normally undergo rapid, partial proteolysis on the endothelial cell
surface by a VWF-specific cleaving protease termed ADAMTS13
[35,36]. ADAMTS13 cleaves the Y1605/M1606 peptide bond in
Figure 4. Plasma ADAMTS13 activity inhibition in P. falciparum
malaria. (A&B) To investigate further the mechanisms responsible for
the marked and discrepant increase in plasma VWF:CB, and the
significant reduction in ADAMTS13 activity, we investigated the effects
of mixing malaria plasma with normal plasma. Plasma from four
different children (%,$,n,X) with SM (each with baseline ADAMTS13
activities of ,0.4 U/dl) were mixed in various proportions with pooled
normal plasma, and ADAMTS13 activity determined. No evidence of an
immediate ADAMTS13 inhibitor effect was observed (Fig 4A). However
following incubation at 37uC for 15 min or 30 min (Fig 4B), significant
ADAMTS13 inhibition was observed in malaria plasmas at either
75%:25% (m), or 50%:50% ($), but not in normal control plasma (%).
All results represent mean6SEM. (C) To further investigate whether
malarial plasma contained an ADAMTS13 inhibitor, individual malaria
plasma samples (n = 4) and control plasmas (n = 4) were spiked with
recombinant human ADAMTS13. Again, significant inhibition of
rADAMTS13 activity (means6SEM) was observed only in malaria plasma
(X) but not in normal plasma (&).
doi:10.1371/journal.ppat.1000349.g004
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the VWF A2 domain, thereby preventing the accumulation of
ULVWF multimers in normal plasma, and thus also regulating
VWF functional activity [23,36]. However, it remains largely
unclear how VWF proteolysis by ADAMTS13 is regulated in-vivo,
although recent studies have identified some putative mechanisms of
cofactor enhancement [29] and inhibition [19] respectively. In this
study, we demonstrate that plasma ADAMT13 antigen and activity
levels are both significantly reduced in children with CM or SM at
presentation (Fig 3). This finding differs from early P. falciparum
malaria, where plasma ADAMTS13 levels were previously reported
to be within the normal range [12]. Decreased plasma ADAMTS13
antigen level may be partly attributable to a reduction in hepatic
ADAMTS13 synthesis. However, increased consumption of
ADAMTS13 in the setting of sustained, systemic release of ULVWF
has also been previously described [37]. Interestingly, ADAMTS13
antigen and activity levels did not improve significantly during the
72 hours following commencement of anti-malarial therapy in
children with CM (Fig 3). In contrast, we observed a significant fall in
VWF collagen binding activity (and VWF propeptide) over this time
period, but not in plasma VWF antigen levels. Cumulatively, these
data suggest that acute EC activation and ongoing WP body
secretion are essential in order to maintain circulating ULVWF in P.
falciparum malaria.
Although ADAMTS13 antigen and activity were both signifi-
cantly reduced in children with severe P. falciparum malaria compared
to normal controls, absolute plasma ADAMTS13 levels remained
above 50% (median 0.63 U/ml or 63%). These novel data are in
keeping with those of Nguyen et al., who reported a similar reduction
in ADAMTS13 activity (mean 57.4%) in children with non-malarial
severe sepsis [25]. Furthermore, Sosothikul et al also observed
comparable reductions in plasma ADAMTS13 activity in a cohort of
paediatric patients with Dengue virus [38]. The correlation between
these respective data is noteworthy, given that different methods
(FRETS-VWF75; full-length VWF cleavage; and flow chamber
assay) were used in the three studies to determine plasma
ADAMTS13 activity. Nevertheless, whether this modest reduction
in plasma ADAMTS13 plays an important role in mediating the
ULVWF accumulation in severe malaria remains unclear. Previous
studies have suggested that ADAMTS13 activity levels above 10%
are sufficient to maintain normal plasma VWF multimer composi-
tion, at least in the absence of any associated acute EC activation
[39]. Consequently, it seems likely that in-vivo inhibition of plasma
ADAMTS13 activity may also be occurring in children with CM or
SM respectively.
To further investigate the mechanism(s) responsible for the
persistence of ULVWF in the presence of reduced but significant
Figure 5. Severe P. falciparum malaria and plasma ADAMTS13 inhibitor levels. (A&B) In children with CM or SM, plasma IL-6 levels
(means6SEM) were significantly increased compared to those in normal controls. However the absolute concentrations of IL-6 did not reach that
previously described as being required to inhibit ADAMTS proteolysis of VWF, and in spiking experiments we found no inhibitory effect of IL-6 (final
concentration range 0.01–10 mg/ml) on ADAMTS13 activity in pooled normal plasma (FRETS-VEF73 assay). (C) Reduced plasma FVIII levels have
recently been reported to inhibit ADAMTS13 activity but plasma FVIII:C levels (means6SEM) were significantly increased in children with severe P.
falciparum malaria. (D) Although, intravascular haemolysis is a recognised complication of malarial infection, and free plasma haemoglobin has been
shown to inhibit ADAMTS13 activity, only minor increased plasma haemoglobin concentrations were observed in children with CM or SM, well below
that previously described to significantly inhibit ADAMTS13 activity. (* p,0.05; ** p,0.005; *** p,0.0005).
doi:10.1371/journal.ppat.1000349.g005
Malaria, VWF and ADAMTS13 Inhibition
PLoS Pathogens | www.plospathogens.org 6 March 2009 | Volume 5 | Issue 3 | e1000349
residual ADAMTS13, we investigated ADAMTS13 activity
inhibition in malarial plasma. Using a FRETS-VWF73 assay to
quantify residual ADAMTS13 activity, moderate time-dependent
inhibition of the ADAMTS13 activity in normal pooled plasma
was observed following incubation with an equal volume of
malarial plasma. Furthermore, similar inhibition was clearly
apparent when recombinant human ADAMTS13 was spiked into
malarial plasma, but not into normal plasma (Fig 3). Cumulatively,
these findings support the hypothesis that severe P. falciparum
plasma may contain an inhibitor of ADAMTS13 activity.
However, current in vitro ADAMTS13 assays are performed under
non-physiological conditions (low ionic strength buffer containing
barium and urea). Consequently, it is difficult to reliably
extrapolate in vitro results to VWF processing in vivo, and
consequent translational significance.
Although the mechanisms underlying the physiological regula-
tion of ADAMTS13 enzymatic activity are not well-defined,
previous studies have identified several putative inhibitors, including
IL-6, TSP-1, thrombin, free plasma haemoglobin, and reduced
FVIII (FVIII:C) levels [19,26–29,39]. In keeping with previous
reports, we observed significantly elevated plasma IL-6 levels in
children with both CM and SM respectively (Fig 5) [40,41]. Plasma
haemoglobin levels were also slightly increased in both groups of
children. However, the absolute plasma concentrations of both IL-6
and haemoglobin were well below those previously reported to
significantly ADAMTS13 activity in-vitro [26,28]. Whether these
inhibitors might interact synergistically, or indeed whether their true
in-vivo inhibitory capacity is accurately reflected in an ex-vivo
ADAMTS13 functional assay remains unclear [39]. Finally, and
again in keeping with previous studies, consumption of coagulation
factor VIII (a recently described ADAMST13 cofactor [29]) was not
a feature of severe P. falciparum malaria. Thus the mechanism
responsible for ADAMTS13 inhibition in malarial plasma remains
unknown, and cannot be explained by quantitative variation in any
of the previously reported plasma ADAMTS13 inhibitors.
In conclusion, based upon our findings we propose that the
presence of hyper-reactive ULVWF multimers in the plasma of
children with severe P. falciparum malaria is the result of (i) acute EC
activation and release of ULVWF from WP bodies; (ii) significantly
reduced plasma ADAMTS13 antigen levels (iii) a circulating but
unidentified inhibitor of human ADAMTS13 activity. Further studies
will be required in order to determine the relative importance of each
of these three components, and to characterize the molecular
mechanisms responsible for ADAMTS13 inhibition. Although we
have demonstrated that ULVWF and ADAMTS13 deficiency are
both associated with CM and SM, it remains unclear whether these
abnormalities constitute epiphenomena, or whether they play active
direct roles in mediating the pathophysiology of the condition.
However, it is well established that abnormal ULVWFmultimers are
also present in the circulation in patients with thrombotic
thrombocytopenic purpura (TTP) [23,36]. This rare life-threatening
condition is characterized by the development of pathological
platelet-rich thrombi in the microvasculature, which in turn results
in end-organ dysfunction, principally involving the brain and kidneys.
Although inherited or acquired deficiencies of ADAMTS13 have
been implicated in the pathogenesis of many cases of TTP [36,42],
recent evidence suggests that ADAMTS13 deficiency is not by itself
sufficient to trigger acute TTP. In particular, ADAMTS13 2/2
mice are viable, exhibit normal survival, and only develop TTP-like
symptoms after specific additional insults (e.g. shigatoxin challenge).
Nevertheless, in view of the critical role played by VWF in mediating
platelet adhesion/aggregation, and the accumulating evidence
suggesting that platelet adhesion/aggregation also facilitate cytoadhe-
sion of IE [43], it seems entirely plausible that ULVWF multimers
may indeed be involved in mediating the pathophysiology of severe P.
falciparum malaria.
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